Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.
Allergic asthma
Efficacy
Long-term
Omalizumab
Pediatric
Safety
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
16
05
2022
revised:
02
08
2022
accepted:
17
08
2022
entrez:
18
10
2022
pubmed:
19
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness in the real world have been reported in numerous studies. In this review, we examine clinical evidence in pediatric and adult patients with allergic asthma who received omalizumab treatment for at least 2 years, to assess its effectiveness, durability, and trajectory of response over time as well as safety. We performed a literature search from inception until March 2022 in PubMed using the keywords "omalizumab" and "allergic asthma" to retrieve articles examining the effects of omalizumab in patients with allergic asthma, aged ≥6 years. Only articles that evaluated the effectiveness of omalizumab for at least 2 years were included. Data from case reports were excluded. Our review confirmed the long-term effectiveness and safety of omalizumab, demonstrating reduced rate of exacerbations, improved lung function, asthma control, and quality of life, decreased health care resource utilization, and use of corticosteroids (oral/inhaled) with a favorable safety and tolerability profile for up to 9 years in adult patients with moderate-to-severe allergic asthma. Similar results were also observed in the pediatric population with up to 7.5 years of omalizumab treatment. This review highlights and confirms the sustained clinical benefits of omalizumab over long periods of treatment in pediatric and adult populations with allergic asthma.
Identifiants
pubmed: 36254180
doi: 10.1016/j.waojou.2022.100695
pii: S1939-4551(22)00071-0
pmc: PMC9519799
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100695Informations de copyright
© 2022 Published by Elsevier Inc. on behalf of World Allergy Organization.
Références
Ther Adv Respir Dis. 2012 Apr;6(2):87-95
pubmed: 22323442
J Asthma Allergy. 2009 May 08;2:49-62
pubmed: 21437144
Biol Ther. 2014 Dec;4(1-2):57-67
pubmed: 25371373
Pediatr Allergy Immunol. 2015 Sep;26(6):551-6
pubmed: 25963882
Pulm Pharmacol Ther. 2019 Feb;54:25-30
pubmed: 30414440
Eur Respir J. 2015 Sep;46(3):856-9
pubmed: 26022964
Respiration. 2012;83(6):520-8
pubmed: 22236804
J Asthma. 2011 May;48(4):387-92
pubmed: 21391878
Eur Respir J. 2017 Nov 30;50(5):
pubmed: 29191955
Eur Respir Rev. 2020 Feb 5;29(155):
pubmed: 32024721
Curr Med Res Opin. 2011 Jan;27(1):45-53
pubmed: 21083517
Eur Respir Rev. 2015 Dec;24(138):594-601
pubmed: 26621973
Clin Exp Allergy. 2009 Jun;39(6):788-97
pubmed: 19302249
Ann Allergy Asthma Immunol. 2014 Oct;113(4):470-5.e2
pubmed: 24994694
Rev Port Pneumol (2006). 2015 May-Jun;21(3):151-6
pubmed: 25926246
Pediatr Allergy Immunol. 2019 Mar;30(2):159-171
pubmed: 30444939
J Asthma. 2012 Oct;49(8):843-8
pubmed: 22954018
Allergol Immunopathol (Madr). 2014 Jan-Feb;42(1):3-10
pubmed: 23253691
Pulm Pharmacol Ther. 2017 Jun;44:38-45
pubmed: 28302544
Immunol Lett. 2020 Nov;227:81-87
pubmed: 32798500
Respir Med. 2013 Jan;107(1):60-7
pubmed: 23083840
Tuberk Toraks. 2016 Jun;64(2):97-104
pubmed: 27481075
Clin Ther. 2018 Jul;40(7):1140-1158.e4
pubmed: 30049502
J Allergy Clin Immunol. 2020 Feb;145(2):528-536.e1
pubmed: 31145939
Ann Allergy Asthma Immunol. 2003 Aug;91(2):182-8
pubmed: 12952113
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1201-1211
pubmed: 33223095
J Asthma. 2013 Aug;50(6):687-94
pubmed: 23557459
Allergol Int. 2017 Jan;66(1):106-115
pubmed: 27507228
J Allergy Clin Immunol Pract. 2013 Jan;1(1):51-7
pubmed: 24229822
J Asthma. 2012 May;49(4):416-22
pubmed: 22443408
Drug Des Devel Ther. 2016 Jul 26;10:2369-78
pubmed: 27528798
Allergy Asthma Proc. 2015 Jul-Aug;36(4):283-92
pubmed: 26108086
Med Princ Pract. 2018;27(3):260-266
pubmed: 29414831
J Allergy Clin Immunol. 2015 Dec;136(6):1476-1485
pubmed: 26518090
Allergy Asthma Proc. 2021 May 1;42(3):235-242
pubmed: 33980337
Allergol Immunopathol (Madr). 2015 Mar-Apr;43(2):120-6
pubmed: 24780091
J Allergy Clin Immunol. 2017 May;139(5):1489-1495.e5
pubmed: 27639934
Adv Ther. 2020 Jan;37(1):353-363
pubmed: 31741282
Pulm Pharmacol Ther. 2014 Oct;29(1):74-9
pubmed: 24508951
Allergy. 2005 Mar;60(3):309-16
pubmed: 15679715
Front Immunol. 2020 Jun 18;11:1134
pubmed: 32625205
Immunol Lett. 2014 Nov;162(1 Pt A):2-10
pubmed: 25194755
Postepy Dermatol Alergol. 2019 Feb;36(1):34-43
pubmed: 30858777
Respir Med. 2013 Aug;107(8):1141-51
pubmed: 23721684
Allergy. 2019 May;74(5):999-1003
pubmed: 30481388
J Allergy Clin Immunol. 2014 Sep;134(3):560-567.e4
pubmed: 24679845
Pediatr Allergy Immunol. 2021 Jul;32(5):980-991
pubmed: 33619748
J Allergy Clin Immunol. 2017 Jul;140(1):162-169.e2
pubmed: 27826098
Allergy Asthma Clin Immunol. 2013 Dec 04;9(1):47
pubmed: 24305549
Pharmacoecon Open. 2019 Sep;3(3):333-342
pubmed: 30684255
Pediatrics. 2001 Aug;108(2):E36
pubmed: 11483846
Allergy Asthma Immunol Res. 2017 Jul;9(4):368-372
pubmed: 28497924
Allergy Asthma Proc. 2012 Mar-Apr;33(2):172-7
pubmed: 22525394
Ann Allergy Asthma Immunol. 2016 Nov;117(5):546-549
pubmed: 27788886
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84
pubmed: 22697079
Respir Med. 2009 Aug;103(8):1098-113
pubmed: 19362459
Eur Respir J. 2019 Aug 29;54(2):
pubmed: 31273040
Allergol Immunopathol (Madr). 2019 Jul - Aug;47(4):336-341
pubmed: 30509559
Respir Med. 2016 Oct;119:141-149
pubmed: 27692136
J Allergy Clin Immunol. 2017 May;139(5):1678-1680
pubmed: 28108337
Eur Respir J. 2007 Sep;30(3):452-6
pubmed: 17537763
Pulm Pharmacol Ther. 2012 Feb;25(1):77-82
pubmed: 22155001
Respir Med. 2017 Mar;124:36-43
pubmed: 28284319
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
pubmed: 24414989
Pulm Pharmacol Ther. 2015 Apr;31:123-9
pubmed: 25281265
Respir Med. 2017 Sep;130:55-60
pubmed: 29206634
Postepy Dermatol Alergol. 2017 Oct;34(5):439-447
pubmed: 29507558